US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Articles published by Forte Biosciences, Inc.

News headline image
argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class Anti-CD122 Antibody, FB102, to Its Immunology Pipeline
From Forte Biosciences, Inc.
Via Business Wire
Tickers ARGX FBRX
News headline image
FB102 Achieves Statistically Significant Improvement in Vitiligo at Week 24 After Completion of 12-Week Treatment Period
From Forte Biosciences, Inc.
Via Business Wire
Tickers FBRX
News headline image
Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules
From Forte Biosciences, Inc.
Via Business Wire
Tickers FBRX
News headline image
Forte Biosciences, Inc. Announces First Quarter 2026 Results and Provides Update
From Forte Biosciences, Inc.
Via Business Wire
Tickers FBRX
News headline image
Forte Biosciences Announces Pricing of $150 Million Public Offering
From Forte Biosciences, Inc.
Via Business Wire
Tickers FBRX
News headline image
Forte Biosciences Announces Proposed Public Offering
From Forte Biosciences, Inc.
Via Business Wire
Tickers FBRX
News headline image
Forte Biosciences, Inc. Announces 2025 Results and Provides Update
From Forte Biosciences, Inc.
Via Business Wire
Tickers FBRX
News headline image
Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules
From Forte Biosciences, Inc.
Via Business Wire
Tickers FBRX
News headline image
Forte Biosciences, Inc. Reports Inducement Grants Under NASDAQ Listing Rules
From Forte Biosciences, Inc.
Via Business Wire
Tickers FBRX
News headline image
Forte Biosciences, Inc. to Present at Upcoming Investor Meetings
From Forte Biosciences, Inc.
Via Business Wire
Tickers FBRX
News headline image
Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules
From Forte Biosciences, Inc.
Via Business Wire
Tickers FBRX
News headline image
Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules
From Forte Biosciences, Inc.
Via Business Wire
Tickers FBRX
News headline image
Forte Biosciences, Inc. Announces Third Quarter 2025 Results and Provides Update
From Forte Biosciences, Inc.
Via Business Wire
Tickers FBRX
News headline image
Forte Biosciences, Inc. to Present at Upcoming Healthcare Conferences
From Forte Biosciences, Inc.
Via Business Wire
Tickers FBRX
News headline image
Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules
From Forte Biosciences, Inc.
Via Business Wire
Tickers FBRX
News headline image
Forte Biosciences, Inc. Announces Presentation of FB102 Celiac Disease Trial at Tampere Celiac Disease Symposium
From Forte Biosciences, Inc.
Via Business Wire
Tickers FBRX
News headline image
Forte Biosciences, Inc. Announces Results and Provides Update
From Forte Biosciences, Inc.
Via Business Wire
Tickers FBRX
News headline image
Forte Biosciences Announces Pricing of $75 Million Public Offering
From Forte Biosciences, Inc.
Via Business Wire
Tickers FBRX
News headline image
Forte Biosciences Announces Proposed Public Offering
From Forte Biosciences, Inc.
Via Business Wire
Tickers FBRX
News headline image
Forte Biosciences Announces Positive Data in FB102 Celiac Disease Phase 1B Study
From Forte Biosciences, Inc.
Via Business Wire
Tickers FBRX
News headline image
Forte Biosciences, Inc. Announces Results and Provides Update
From Forte Biosciences, Inc.
Via Business Wire
Tickers FBRX
News headline image
Forte Biosciences, Inc. Announces Results and Provides Clinical Update
From Forte Biosciences, Inc.
Via Business Wire
Tickers FBRX
News headline image
Forte Biosciences, Inc. to Present at Upcoming Investor Meetings
From Forte Biosciences, Inc.
Via Business Wire
Tickers FBRX
News headline image
Forte Biosciences to Host R&D Day December 3, 2024
From Forte Biosciences, Inc.
Via Business Wire
Tickers FBRX
News headline image
Forte Biosciences, Inc. Announces Oversubscribed $53 Million Private Placement From Leading Healthcare Institutional Investors to Advance FB102 Across Autoimmune Indications
From Forte Biosciences, Inc.
Via Business Wire
Tickers FBRX
News headline image
Forte Biosciences, Inc. Announces Third Quarter 2024 Results and Provides Business Update
From Forte Biosciences, Inc.
Via Business Wire
Tickers FBRX
News headline image
Forte Biosciences, Inc. Announces Second Quarter 2024 Results and Provides Business Update
From Forte Biosciences, Inc.
Via Business Wire
Tickers FBRX
News headline image
Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules
From Forte Biosciences, Inc.
Via Business Wire
Tickers FBRX
News headline image
Forte Biosciences, Inc. Announces First Quarter 2024 Results and Provides Business Update
From Forte Biosciences, Inc.
Via Business Wire
Tickers FBRX
News headline image
Forte Biosciences, Inc. Announces 2023 Results and Provides Business Update
From Forte Biosciences, Inc.
Via Business Wire
Tickers FBRX